A Vanadium(II) Photosensitizer Delivered by Human Serum Albumin for Photodynamic Therapy
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01764 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zisis Papadopoulos und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Faculty of Medicine, Ruhr University Bochum, Universitätsstrasse 150, 44801Bochum, Germany. Hauptthemen laut MEDLINE: Photosensitizing Agents, Photochemotherapy, Vanadium, Serum Albumin, Human. Die Arbeit nennt 106 Literaturangaben. Gefördert von: Paul-Ehrlich-Gesellschaft Stiftung, Mercator Research Center Ruhr, Aventis Foundation.
Abstract (Originalsprache)
Photodynamic therapy (PDT) is an established clinically approved treatment; however, the development of next-generation photosensitizers remains constrained by the reliance on scarce precious-metal scaffolds and poor pharmacological properties. Earth-abundant first−row transition metals offer an attractive alternative, but their application in PDT remains underexplored. Herein, we report the first vanadium(II) photosensitizer for PDT and show that its biological activity can be unlocked through loading into human serum albumin (HSA), a strategy intended to improve its pharmacological properties. The resulting HSA-bound complex showed negligible dark toxicity and induced pronounced light-dependent cytotoxicity upon blue- and red-light irradiation in human colon carcinoma cells. Mechanistic studies revealed that the HSA-bound complex preferentially accumulates in lysosomes, where red-light irradiation triggers singlet oxygen generation and promotes apoptosis. This work establishes vanadium(II) complexes as a new class of photosensitizers for photodynamic therapy and opens new opportunities for the design of first-row transition-metal photosensitizers with improved photophysical properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics, Faculty of Medicine, Ruhr University Bochum, Universitätsstrasse 150, 44801Bochum, Germany.
- Center for Protein Diagnostics (PRODI), Ruhr University Bochum, Gesundheitscampus 4, 44801Bochum, Germany.
- Faculty of Chemistry and Biochemistry, Ruhr University Bochum, Universitätsstrasse 150, 44780Bochum, Germany.
- Department of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, 55128Mainz, Germany.
ORCID-Profile: Katja Heinze, Johannes Karges
Förderung
- Paul-Ehrlich-Gesellschaft Stiftung
- Mercator Research Center Ruhr
- Aventis Foundation
- Deutsche Forschungsgemeinschaft
- Fonds der Chemischen Industrie
Zitieren
APA
Papadopoulos, Z., Irgel, A. M., König-Schäfer, A., Heinze, K., & Karges, J. (2026). A Vanadium(II) Photosensitizer Delivered by Human Serum Albumin for Photodynamic Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01764
Vancouver
Papadopoulos Z, Irgel AM, König-Schäfer A, Heinze K, Karges J. A Vanadium(II) Photosensitizer Delivered by Human Serum Albumin for Photodynamic Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01764
BibTeX
@article{Papadopoulos2026,
author = {Papadopoulos, Zisis and Irgel, Aimée Marie and König-Schäfer, Alexandra and Heinze, Katja and Karges, Johannes},
title = {A Vanadium(II) Photosensitizer Delivered by Human Serum Albumin for Photodynamic Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01764}
}
EUVIMED